Reading SRTS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SRTS free→Reading SRTS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SRTS free→NASDAQHealth CareMedical DevicesSnapshot 2026-06-16
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is weak, and the company was unprofitable over the past year, so its earnings quality can't be assessed. Management's recent track record has been steady, but risk is high, and the sector backdrop is a headwind. Peer multiples imply a price about 67% above where it trades (it looks cheap on this basis); the read is cheap, value-trap risk, as it trades below peer multiples while recent financials are weak. If SRTS cuts guidance on the next call, that's a meaningful negative. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 2 valuation methods, at three horizons. Current price $2.71. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $2.71 SRTS trades at 2× p/s, below its 3× p/s peer median. Our $8.53 fair value sits above the price; low confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 67% below a flat-multiple fair value, below our forecast of about -50%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
No fragility gates fired. Regime (Mania) does not concentrate fragility.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 55% of the time over the next year (vs 54% for the rest of the cohort, n=2391).
Over the trailing year it converted 0.07x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
4 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.06 → $-0.10 (-52.8% / 30d). 0 raised, 2 cut, 3 covering analysts.
0 upgrades, 0 downgrades / 30d. 100% of analysts rate Buy.
0 positive, 0 negative / 30d.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$178.
How much price usually moves either way.
On a bad day, this stock has moved -$468.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $5,239.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
Confidence changed from 'medium' to 'high'.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: The earnings report will show how Sensus Healthcare is doing financially and in the market.
Confirms one read:Earnings report shows revenue growth or better margins compared to last quarter.
Confirms the other:Earnings report shows ongoing losses or falling revenue.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for SRTS yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Entry into a Material Definitive Agreement. On June 2, 2026, Sensus Healthcare, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with City National Bank of Florida (“CNB”) pursuant to which CNB has made available to the Company a revolving credit facility providing for maximum borrowings of $15,000,000 (the “Loan”), which is evidenced by a Revolving Promissory Note, dated June 2, 2026 (the “Note”), made by the Company in favor of CNB. Pursuant to the terms of the Note…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Equipment.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
SRTS Sensus Healthcare Inc | Typical Show detailsSector percentile: 44 of 100 | inexpensive | high |
ABT Abbott Laboratories | Above typical Show detailsSector percentile: 92 of 100 | fair | moderate |
ISRG Intuitive Surgical | Above typical Show detailsSector percentile: 94 of 100 | expensive | moderate |
SYK Stryker Corporation | Above typical Show detailsSector percentile: 71 of 100 | fair | moderate |
MDT Medtronic | Above typical Show detailsSector percentile: 89 of 100 | fair | moderate |
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Sensus Healthcare has secured a $15M revolving credit facility with City National Bank of Florida.
Why it matters: Updates on the credit agreement can show Sensus Healthcare's money health and access to funds.
Confirms one read:A press release explains good terms or more borrowing power under the credit agreement.
Confirms the other:News of bad terms or less borrowing power under the credit agreement.
Results of Operation and Financial Condition On May 7, 2026, Sensus Healthcare, Inc. announced via press release its financial results for the first quarter of 2026. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The press release makes reference to certain non-GAAP financial measures. A reconciliation of the non-GAAP financial measures and other financial information is provided in the press release. The informati…
Results of Operation and Financial Condition On February 12, 2026, Sensus Healthcare, Inc. announced via press release its financial results for the quarter and year ended December 31, 2025. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The press release makes reference to certain non-GAAP financial measures. A reconciliation of the non-GAAP financial measures and other financial information is provided in the pre…
Changes in Registrant’s Certifying Accountant Sensus Healthcare, Inc. (the “Company”) was notified that Carr, Riggs & Ingram, LLC (“CRI”) acquired, effective as of January 1, 2026, certain assets related to the capital markets practice of Berkowitz Pollack Brant Advisors + CPAs, LLP (“BPB”). On January 13, 2026, the Audit Committee of the Company’s Board of Directors simultaneously dismissed BPB as the Company’s independent registered public accounting firm and approved the appointment of CRI…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (d) On January 5, 2026, the Board of Directors (the “Board”) of Sensus Healthcare, Inc. (the “Company”) appointed Larry Biscotti as a Class I director of the Company for a term expiring at the Company’s annual meeting in 2028. There are no arrangements or understandings between Mr. Biscotti and any other persons pursuant to which he was elected, nor…